Use of cevimeline, a muscarinic M1 and M3 agonist, in the treatment of Sjögren's syndrome

Advances in Experimental Medicine and Biology

Volumn 506 B, Issue , 2002, Pages 1107-1116

  Fox, Robert I ^a  

^a SCRIPPS MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEVIMELINE; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC RECEPTOR; PILOCARPINE; PLACEBO;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG USE; HUMAN; PRIORITY JOURNAL; SALIVATION; SJOEGREN SYNDROME;

EID: 0036926248     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-0717-8_155     Document Type: Conference Paper

References (51)

1. Fox, R., Classification Criteria for Sjogren's syndrome. Rheumatic Disease Clinics of North America: Current Controversies in Rheumatology, 1994. 20: p. 391-407.
2. Vitali, C. and S. Bombardieri, The Europian classification criteria for Sjogren's syndrome (SS): proposal for modification of the rules for classification suggested by the analysis of the receiver operating characteristic (ROCS) curve of the criteria performance. J. Rheum, 1997. 24 (supplement): p. S18.
3. Nelson, J.D., Diagnosis of keratoconjunctivitis sicca. Int Ophthalmol Clin, 1994. 34(1): p. 37-56.
4. Watanabe, H., et al., Human corneal and conjunctival epithelia produce a mucin-like glycoprotein for the apical surface. Invest Ophthalmol Vis Sci, 1995. 36(2): p. 337-44.
5. Fox, R.I., M. Stern, and P. Michelson, Update in Sjogren syndrome [In Process Citation]. Curr Opin Rheumatol, 2000. 12(5): p. 391-8.
6. Lemp, M.A., Tear film: new concepts and implications for the management of the dry eye. Trans New Orleans Acad Ophthalmol, 1987. 35: p. 53-64.
7. Fox, R.I., et al., Evolving concepts of diagnosis, pathogenesis, and therapy of Sjogren's syndrome. Curr Opin Rheumatol, 1998. 10(5): p. 446-56.
8. Stem M.E., et al., A unified theory of the role of the ocular surface in dry eye. Adv Exp Med Biol, 1998. 438: p. 643-51.
9. Andoh, Y., et al., Morphometric analysis of secretory glands in Sjögren's syndrome. Am Rev Respir Dis, 1993. 148(5): p. 1358-62.
10. Daniels, T.E. and J.P. Whitcher, Association of patterns of labial salivary gland inflammation with keratoconjunctivitis sicca. Analysis of 618 patients with suspected Sjogren's syndrome. Arthritis Rheum, 1994. 37(6): p. 869-77.
11. Kovacs L., et al. Impaired microvascular response to cholinergic stimuli in primary Sjogren's syndrome. Ann Rheum Dis, 2000. 59(1): p. 48-53.
12. Main, C., P. Blennerhassett, and S.M. Collins, Human recombinant interleukin 1 beta suppresses acetylcholine release from rat myenteric plexus. Gastroenterology, 1993. 104(6): p. 1648-54.
13. Quirion, R., et al., Growth factors and lymphokines: modulators of cholinergic neuronal activity. Can J Neurol Sci, 1991. 18(3 Suppl): p. 390-3.
14. Bacman, S.R., et al., Human primary Sjogren's syndrome autoantibodies as mediators of nitric oxide release coupled to lacrimal gland muscarinic acetylcholine receptors. Curr Eye Res, 1998. 17(12): p. 1135-42.
15. Waterman, S.A., T.P. Gordon, and M. Rischmueller, Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjogren's syndrome. Arthritis Rheum, 2000. 43(7): p. 1647-54.
16. Kong, L., et al., Fas and Fas ligand expression in the salivary glands of patients with primary Sjogren's syndrome. Arthritis Rheum, 1997. 40(1): p. 87-97.
17. Liu, X.B., et al., G-protein signaling abnormalities mediated by CD95 in salivary epithelial cells. Cell Death Differ, 2000. 7(11): p. 1119-1126.
18. Tominaga, M., et al. Expression of metalloproteinase-2 (gelatinase A) in labial salivary glands of patients with Sjogren's, syndrome with HTLV-1 infection. Clin Exp Rheumatol, 1999. 17(4): p. 463-6.
19. Azuma, M., et al., Suppression of tumor necrosis factor alpha-induced matrix metalloproteinase 9 production by the introduction of a super-repressor form of inhibitor of nuclear factor kappaBalpha complementary DNA into immortalized human salivary gland acinar cells. Prevention of the destruction of the acinar structure in Sjogren's syndrome salivary glands. Arthritis Rheum, 2000. 43(8): p. 1756-67.
20. Laurie, G.W., et al., Immunological and partial sequence identity of mouse BM180 with wheat alphagliadin. Biochem Biophys Res Commun, 1995. 217(1): p. 10-5.
21. Pflugfelder, S.C., et al., Conjunctival cytologic features of primary Sjogren's syndrome. Ophthalmology, 1990. 97(8): p. 985-91.
22. Jones, D.T., et al., Alterations of ocular surface gene expression in Sjogren's syndrome. Adv Exp Med Biol, 1998. 438: p. 533-6.
23. Marsh, P. and S.C. Pflugfelder, Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology, 1999. 106(4): p. 811-6.
24. Liu, Z., et al., Increased expression of the type 1 growth factor receptor family in the conjunctival epithelium of patients with keratoconjunctivitis sicca. Am J Ophthalmol, 2000. 129(4): p. 472-480.
25. Baumgold, J., et al., Comparison of second-messenger responses to muscarinic receptor stimulation in M1-transfected A9 L cells. Cell Signal, 1995. 7(1): p. 39-43.
26. Laurie, G., et al., BM180: a novel basement membrane protein with a role in stimulus secretion coupling by lacrimal acinar cells. Am. J. Physiol, 1996. 39: p. C1743-C1750.
27. Wu, A., et al., Effect of tumor necrosis factor alpha and interferon gamma on the growth of a human salivary gland cell line. J. Cell Physiol, 1994. 161: p. 217-226.
28. Wu, A.J., et al., Modulation of MMP-2 (gelatinase A) and MMP-9 (gelatinase B) by interferon-gamma in a human salivary gland cell line. J Cell Physiol, 1997. 171(2): p. 117-24.
29. Cheresh, D.A., J. Leng, and R.L. Klemke, Regulation of cell contraction and membrane ruffling by distinct signals in migratory cells. J Cell Biol, 1999. 146(5): p. 1107-16.
30. Eva, C., J.L. Meek, and E. Costa, Vasoactive intestinal peptide which coexists with acetylcholine decreases acetylcholine turnover in mouse salivary glands. J Pharmacol Exp Ther, 1985. 232(3): p. 670-4.
31. Yamamoto, H., et al., Detection of alterations in the levels of neuropeptides and salivary gland responses in the non-obese diabetic mouse model for autoimmune sialoadenitis. Scand J Immunol, 1997. 45(1): p. 55-61.
32. Humphreys-Beher, M.G. and A.B. Peck, New concepts for the development of autoimmune exocrinopathy derived from studies with the NOD mouse model. Arch Oral Biol, 1999. 44 Suppl 1: p. S21-5.
33. Robinson, C.P., et al., Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjogren's syndrome. Proc Natl Acad Sci U S A, 1998. 95(13): p. 7538-43.
34. Dawson, L.J., S.E. Christmas, and P.M. Smith, An investigation of interactions between the immune system and stimulus- secretion coupling in mouse submandibular acinar cells. A possible mechanism to account for reduced salivary flow rates associated with the onset of Sjogren's syndrome. Rheumatology (Oxford), 2000. 39(11): p. 1226-33.
35. Wotta, D.R., et al., M1, M3 and M5 muscarinic receptors stimulate mitogen-activated protein kinase. Pharmacology, 1998. 56(4): p. 175-86.
36. Lu, G., et al., Tumor necrosis factor-alpha and interleukin-1 induce activation of MAP kinase and SAP kinase in human neuroma fibroblasts. Neurochem Int, 1997. 30(4-5): p. 401-10.
37. Fisher, A., et al., (+-)-cis-2-methyl-spiro(1,3-oxathiolane.5,3′) quinuclidine (AF102B): a new M1 agonist attenuates cognitive dysfunctions in AF64A-treated rats. Neurosci Lett, 1989. 102(2-3): p. 325-31.
38. Fisher, A., Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists. Jpn J Pharmacol, 2000. 84(2): p. 101-12.
39. Iga, Y., et al., (+/-)-cis-2-methylspiro[1,3-oxathiolane.5,3′-quinuclidine] hydrochloride, hemihydrate (SN1-2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: the role of muscarinic acetylcholine receptors. Jpn J Pharmacol, 1998. 78(3): p. 373-80.
40. Fox, R., et al., Randomized, placebo controlled trial of SN1-2011, a novel M3 muscarinic receptor agonist, for the treatment of Sjogrenn's syndrome. Arth Rheum, 1998. 41 (supplement): p. S288.
41. Masunaga, H., et al., Long-lasting salivation induced by a novel muscarinic receptor agonist SN1-2011 in rats and dogs. Eur J Pharmacol, 1997. 339(1): p. 1-9.
42. Iwabuchi, Y. and T. Masuhara, Sialogogic activities of SN1-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: identification of a potential therapeutic agent for treatment of Sjorgen's syndrome. Gen Pharmacol, 1994. 25(1): p. 123-9.
43. Iwabuchi, Y., M. Katagiri, and T. Masuhara, Salivary secretion and histopathological effects after single administration of the muscarinic agonist SN1-2011 in MRL/lpr mice. Arch Int Pharmacodyn Ther, 1994. 328(3): p. 315-25.
44. Nagler, R.M., D. Laufer, and A. Nagler, Parotid gland dysfunction in an animal model of chronic graft-vs-host disease. Arch Otolaryngol Head Neck Surg, 1996. 122(10): p. 1057-60.
45. Fisher, A., et al., Selective signaling via unique M1 muscarinic agonists. Ann N Y Acad Sci, 1993. 695: p. 300-3.
46. Leloup, C., et al., M1 muscarinic receptors block caspase activation by phosphoinositide 3-kinase- and MAPK/ERK-independent pathways. Cell Death Differ, 2000. 7(9): p. 825-33.
47. Fox, P.C., et al., Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia). Arch Intern Med, 1991. 151(6): p. 1149-52.
48. Greenspan, D. and T.E. Daniels, Effectiveness of pilocarpine in postradiation xerostomia. Cancer, 1987. 59: p. 1123-1125.
49. Johnson, J.T., et al., Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer [see comments]. N Engl J Med 1993. 329(6): p. 390-5.
50. Vivino, F.B., et al., Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group [In Process Citation]. Arch Intern Med, 1999. 159(2): p. 174-81.
51. Fox R. et al. Randomized placebo controlled trial of SN1-2011, a novel M3 muscarinic receptor agonist, for the treatment of Sjogrenn's syndrome. Arth Rheum, 1998. 41 (supplement): p. S288.